tirzepatide patent expiry in india looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs India Tightens Checks On GLP-1

The decision could reshape how Americans access peptides, siding with popular demand over warnings from the agency's own scientists

Effective patient selection is paramount

This article covers the biological mechanisms validated in animal studies, the dosing protocols used in published research, the regulatory gap that keeps human trials absent, and what current evidence suggests about practical applications for athletes dealing with recurring ankle instability

A solution can look clear while still having degraded or lost a trustworthy storage history

In 2025, a landmark study revealed that patients with severe obesity lost an average of 11.9% of their body weight after a year of consistent injectable therapies like semaglutide

Depending on how you are doing, you may be scheduled for another set of labs.** Am I a Good Candidate for Semaglutide Treatments